Banafsheh Arshi

Banafsheh Arshi

Auto-generated profile, based on publicly available information

Banafsheh Arshi

Department of Epidemiology, CAPHRI Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Peter Debyeplein 1, P.O. Box 616, Maastricht, 6200 MD, The Netherlands, 31 433882821

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2025 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
BABanafsheh Arshi
Banafsheh Arshi
LCLaura Elizabeth Cowley
Laura Elizabeth Cowley
EREline Rijnhart
Eline Rijnhart
KRKelly Reeve
Kelly Reeve
LSLuc J. Smits
Luc J. Smits
LWLaure Wynants
Laure Wynants
We aimed to assess paths taken by clinical prediction models (CPMs) after development by quantifying external validation, impact assessment, and utilization in clinical practice. We followed a random sample of 109 regression-based CPM development articles published between 1995 and 2020 by performing a forward citation search. We estimated 5- and 10-year probabilities of validation and impact assessment after development of CPMs using Kaplan-Meier analysis. In addition, we conducted a survey among the authors of the development articles to determine whether the CPMs had been used in clinical settings. Eighteen (17%) CPM development articles reported a CPM that was externally validated after development. Five- and 10-year probabilities of validation were 0.13 (0.06-0.19) and 0.16 (0.08-0.23), respectively. Only 1 article had a CPM with impact assessment during follow-up (10-year probability: 0.01 [0-0.04]). Among the 34 (31%) articles with a survey response, 17 (50%) had CPMs that had been used in clinical practice, in a median of five sites (interquartile range: 1-347). Of these models, only 4 (24%) were externally validated, and none had undergone impact assessment. Despite evidence of utilization in clinical settings, few models are externally validated after development, and published impact assessment is scarce. To prevent compromising patient safety, it is crucial to intensify efforts to promote external validation and impact assessment of prediction models.

4 July 2025 in JMIR Medical Informatics
Verified
Journal Article
Open access
BABanafsheh Arshi
Banafsheh Arshi
LWLaure Wynants
Laure Wynants
EREline Rijnhart
Eline Rijnhart
KRKelly Reeve
Kelly Reeve
LCLaura Elizabeth Cowley
Laura Elizabeth Cowley
LSLuc J Smits
Luc J Smits
Background: Concerns have been expressed about the abundance of new clinical prediction models (CPMs) proposed in the literature. However, the extent of this proliferation in prediction research remains unclear. Objective: This study aimed to estimate the total and annual number of CPM development-related publications available across all medical fields. Methods: Using a validated search strategy, we conducted a systematic search of literature for prediction model studies published in Pubmed and Embase between 1995 and the end of 2020. By taking random samples for each year, we identified eligible studies that developed a multivariable model (ie, diagnostic or prognostic) for individual-level prediction of a health outcome across all medical fields. Exclusion criteria included development of models with a single predictor, studies not involving humans, methodological studies, conference abstracts, articles with unavailable full text, and those not available in English. We estimated the total and annual number of published regression-based multivariable CPM development articles, based on the total number of publications, proportion of included articles, and the search sensitivity. Furthermore, we used an adjusted Poisson regression to extrapolate our results to the period 1950‐2024. Additionally, we estimated the number of articles that developed CPMs using techniques other than regression (eg, machine learning). Results: From a random sample of 10,660 articles published between 1995 and 2020, 109 regression-based CPM development articles were included. We estimated that 82,772 (95% CI 65,313‐100,231) CPM development articles using regression were published, with an acceleration in model development from 2010 onward. With the addition of articles that developed non-regression-based CPMs, the number increased to 147,714 (95% CI 125,201-170,226). After extrapolation to the years 1950‐2024, the number of articles increased to 156,673 and 248,431 for regression-based models and total CPMs, respectively. Conclusions: Based on a representative sample of publications from the literature, we estimated that nearly 250,000 articles reporting the development of CPMs across all medical fields were published until 2024. CPM development–related publications continue to increase in number. To prevent research waste and close the gap between research and clinical practice, focus should shift away from developing new CPMs to facilitating model validation and impact assessment of the plethora of existing CPMs. Limitations of this study include restriction of search to articles available in English and development of the validated search strategy prior to the popularity of artificial intelligence and machine learning models.

3 January 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
BABanafsheh Arshi
Banafsheh Arshi
HAHamid A. Aliahmad
Hamid A. Aliahmad
MIM. Arfan Ikram
M. Arfan Ikram
DBDaniel Bos
Daniel Bos
MKMaryam Kavousi
Maryam Kavousi
Background: Larger epicardial fat volume (EFV) has been associated with increased risks of cardiovascular disease and atrial fibrillation. Yet, evidence on the association of EFV with cardiac function and incident heart failure (HF) remains scarce. Methods and Results: We included 2103 participants (mean age, 68 years; 54.4% women) from the prospective population‐based RS (Rotterdam Study) with computed tomography–based EFV and repeated echocardiography‐based assessment of left ventricular (LV) systolic and diastolic function. Linear mixed effects and Cox‐proportional hazard regression models, adjusted for cardiovascular risk factors, were used to assess the associations of EFV with repeated measurements of echocardiographic parameters and with incident HF. During a median follow‐up of 9.7 years, 124 HF events occurred (incidence rate, 6.37 per 1000 person‐years). For LV systolic function, 1‐SD larger EFV was associated with 0.76 (95% CI, 0.54–0.98) mm larger LV end‐diastolic dimension, 0.66 (95% CI, 0.47–0.85) mm larger LV end‐systolic dimension, and 0.56% (95% CI, −0.86% to −0.27%) lower LV ejection fraction. Interactions between EFV and time were small. For LV diastolic function, 1‐SD larger EFV was associated with 1.02 (95% CI, 0.78–1.27) mm larger left atrial diameter. Larger EFV was also associated with incident HF (hazard ratio per 1‐SD increase in EFV, 1.34 [95% CI, 1.07–1.68] per 1‐SD larger EFV). Conclusions: We report an independent association between EFV with new‐onset HF in the general population. EFV seems to exert its influence on HF through different pathways contributing to deteriorations in systolic function and larger left atrial size in part, likely through mechanical restraint and hypertrophy.

17 May 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
BABanafsheh Arshi
Banafsheh Arshi
LWLaure Wynants
Laure Wynants
EREline Rijnhart
Eline Rijnhart
KRKelly Reeve
Kelly Reeve
LCLaura Elizabeth Cowley
Laura Elizabeth Cowley
LSLuc J Smits
Luc J Smits
Introduction It is known that only a limited proportion of developed clinical prediction models (CPMs) are implemented and/or used in clinical practice. This may result in a large amount of research waste, even when considering that some CPMs may demonstrate poor performance. Cross-sectional estimates of the numbers of CPMs that have been developed, validated, evaluated for impact or utilized in practice, have been made in specific medical fields, but studies across multiple fields and studies following up the fate of CPMs are lacking. Methods and analysis We have conducted a systematic search for prediction model studies published between January 1995 and December 2020 using the Pubmed and Embase databases, applying a validated search strategy. Taking random samples for every calendar year, abstracts and articles were screened until a target of 100 CPM development studies were identified. Next, we will perform a forward citation search of the resulting CPM development article cohort to identify articles on external validation, impact assessment or implementation of those CPMs. We will also invite the authors of the development studies to complete an online survey to track implementation and clinical utilization of the CPMs. We will conduct a descriptive synthesis of the included studies, using data from the forward citation search and online survey to quantify the proportion of developed models that are validated, assessed for their impact, implemented and/or used in patient care. We will conduct time-to-event analysis using Kaplan-Meier plots. Ethics and dissemination No patient data are involved in the research. Most information will be extracted from published articles. We request written informed consent from the survey respondents. Results will be disseminated through publication in a peer-reviewed journal and presented at international conferences. OSF registration (https://osf.io/nj8s9).

1 November 2021 in Atherosclerosis
Verified
Journal Article
Open access
JTJanine E. van der Toorn
Janine E. van der Toorn
DBDaniel Bos
Daniel Bos
BABanafsheh Arshi
Banafsheh Arshi
MLMaarten J.G. Leening
Maarten J.G. Leening
MVMeike W. Vernooij
Meike W. Vernooij
MKMaryam Kavousi
Maryam Kavousi
The sex-specific contributions of arterial calcification to atherosclerotic cardiovascular disease (ASCVD) risk prediction and stratification in the light of recent modifications by cardiovascular prevention guidelines remain unclear. We assessed the sex-specific value of calcification in different arteries, beyond the Pooled Cohort Equations (PCE) risk factors, for 10-year ASCVD risk prediction. From 2003 to 2006, participants from the population-based Rotterdam Study (n = 2167) underwent CT to quantify coronary artery calcification (CAC), aortic arch calcification (AAC), extracranial (ECAC) and intracranial carotid artery calcification (ICAC). Follow-up for ASCVD was complete on January 1, 2015. We refitted the PCE (base model), and categorized participants into low (<5%), borderline (5%-7.5%), intermediate (7.5%-20%), and high (≥20%) ASCVD risk. We extended the models with calcifications and calculated c-statistics and net reclassification improvements for events (NRIe) and non-events (NRIne). CAC predicted ASCVD in women [hazard-ratio (95%-CI) per 1-SD: 1.40 (1.14-1.73)] and men [1.62 (1.27-1.93)]. After addition of CAC to the base model, the c-statistic improved from 0.71 to 0.72 in women; from 0.65 to 0.68 in men. Addition of CAC led to NRIe of 14.3% in women, 4.8% in men and NRIne of 1.5% in women, 15.1% in men. Only in women, ICAC predicted ASCVD [hazard-ratio (95%-CI) per 1-SD: 1.62 (1.26-2.08)], and improved the model (c-statistic from 0.71 to 0.73, NRIe: 9.8% and NRIne: 5.9%). Assessment of CAC improves ASCVD risk prediction and stratification. In women, the added value of ICAC for ASCVD risk prediction is comparable to that of CAC.

19 December 2024 in Diagnostic and Prognostic Research
Verified
Journal Article
Open access
PDF file
JDJohanna A. A. Damen
Johanna A. A. Damen
BABanafsheh Arshi
Banafsheh Arshi
MSMaarten van Smeden
Maarten van Smeden
SBSilvia Bertagnolio
Silvia Bertagnolio
JDJanet V. Diaz
Janet V. Diaz
KMKarel G. M. Moons
Karel G. M. Moons
Background: We evaluated the performance of prognostic models for predicting mortality or ICU admission in hospitalized patients with COVID-19 in the World Health Organization (WHO) Global Clinical Platform, a repository of individual-level clinical data of patients hospitalized with COVID-19, including in low- and middle-income countries (LMICs). Methods: We identified eligible multivariable prognostic models for predicting overall mortality and ICU admission during hospital stay in patients with confirmed or suspected COVID-19 from a living review of COVID-19 prediction models. These models were evaluated using data contributed to the WHO Global Clinical Platform for COVID-19 from nine LMICs (Burkina Faso, Cameroon, Democratic Republic of Congo, Guinea, India, Niger, Nigeria, Zambia, and Zimbabwe). Model performance was assessed in terms of discrimination and calibration. Results: Out of 144 eligible models, 140 were excluded due to a high risk of bias, predictors unavailable in LIMCs, or insufficient model description. Among 11,338 participants, the remaining models showed good discrimination for predicting in-hospital mortality (3 models), with areas under the curve (AUCs) ranging between 0.76 (95% CI 0.71–0.81) and 0.84 (95% CI 0.77–0.89). An AUC of 0.74 (95% CI 0.70–0.78) was found for predicting ICU admission risk (one model). All models showed signs of miscalibration and overfitting, with extensive heterogeneity between countries. Conclusions: Among the available COVID-19 prognostic models, only a few could be validated on data collected from LMICs, mainly due to limited predictor availability. Despite their discriminative ability, selected models for mortality prediction or ICU admission showed varying and suboptimal calibration.